Since their introduction in 2015, the United Nations Sustainable Development Goals (SDGs) encourage innovative solutions to address the world’s health challenges and have achieved global adoption across industries.
SDG 3 – Good Health and Well-being aims to “ensure healthy lives and promote well-being for all at all ages”. Of particular relevance to pharma and biotech are the targets of SDG 3.3, which focuses on ending the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combatting hepatitis, waterborne diseases and communicable diseases; and SDG 3.4, which encourages reducing premature mortality from noncommunicable diseases by one-third through prevention and treatment and promoting mental health and well-being.
The chart below contrasts several of these conditions with NASH, a recent hostspot of R&D activity due in part to its substantial commercial potential in the wealthy world.
